vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and Coeptis Therapeutics Holdings, Inc. (COEP). Click either name above to swap in a different company.
AVAX ONE TECHNOLOGY LTD. is the larger business by last-quarter revenue ($1.0M vs $862.0K, roughly 1.2× Coeptis Therapeutics Holdings, Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -1633.6%, a 1487.1% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
AVX vs COEP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $862.0K |
| Net Profit | $-16.6M | $-1.3M |
| Gross Margin | — | 94.8% |
| Operating Margin | -1522.1% | -230.6% |
| Net Margin | -1633.6% | -146.5% |
| Revenue YoY | — | — |
| Net Profit YoY | -480.2% | 55.1% |
| EPS (diluted) | $32.17 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $862.0K | ||
| Q3 25 | $525.9K | $237.4K | ||
| Q2 25 | $452.0K | $200.7K | ||
| Q1 25 | $344.4K | $62.9K | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $41.3K | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-16.6M | $-1.3M | ||
| Q3 25 | $-8.4M | $-2.9M | ||
| Q2 25 | $-8.1M | $-4.3M | ||
| Q1 25 | $-145.5K | $-3.4M | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | $-5.8M | $-1.8M | ||
| Q2 24 | $-4.2M | $-3.0M | ||
| Q1 24 | — | $-3.0M |
| Q4 25 | — | 94.8% | ||
| Q3 25 | — | 81.0% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | 22.9% | 28.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1522.1% | -230.6% | ||
| Q3 25 | -496.6% | -1043.2% | ||
| Q2 25 | -328.4% | -2252.9% | ||
| Q1 25 | -600.0% | -6452.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2827.7% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1633.6% | -146.5% | ||
| Q3 25 | -1588.0% | -1220.8% | ||
| Q2 25 | -1783.4% | -2159.9% | ||
| Q1 25 | -42.2% | -5440.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10243.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | $32.17 | $0.05 | ||
| Q3 25 | $-5.55 | $-0.58 | ||
| Q2 25 | $-27.60 | $-1.17 | ||
| Q1 25 | $-1.17 | $-1.11 | ||
| Q4 24 | — | $-5.35 | ||
| Q3 24 | $-57.19 | $-0.05 | ||
| Q2 24 | $-83.03 | $-0.08 | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $676.6K |
| Total DebtLower is stronger | — | $150.0K |
| Stockholders' EquityBook value | $187.0M | $13.6M |
| Total Assets | $195.0M | $16.2M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $676.6K | ||
| Q3 25 | $894.7K | $421.7K | ||
| Q2 25 | $185.3K | $990.6K | ||
| Q1 25 | $1.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $150.0K | ||
| Q3 25 | $1.8M | $150.0K | ||
| Q2 25 | $8.6M | $150.0K | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | $150.0K | ||
| Q3 24 | $2.2M | $1.7M | ||
| Q2 24 | $3.1M | $1.7M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | $187.0M | $13.6M | ||
| Q3 25 | $12.2M | $10.4M | ||
| Q2 25 | $4.1M | $6.1M | ||
| Q1 25 | $6.4M | $6.5M | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | $6.7M | $4.8M | ||
| Q2 24 | $11.3M | $-442.6K | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | $195.0M | $16.2M | ||
| Q3 25 | $16.5M | $14.2M | ||
| Q2 25 | $15.2M | $12.2M | ||
| Q1 25 | $16.8M | $13.5M | ||
| Q4 24 | — | $8.9M | ||
| Q3 24 | $10.8M | $9.0M | ||
| Q2 24 | $15.7M | $4.2M | ||
| Q1 24 | — | $3.9M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | 0.15× | 0.01× | ||
| Q2 25 | 2.11× | 0.02× | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | 0.33× | 0.35× | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-8.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-8.6M | ||
| Q3 25 | $-2.4M | $-2.2M | ||
| Q2 25 | $-884.1K | $-2.4M | ||
| Q1 25 | $-2.2M | $-2.4M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $-1.2M | $-1.9M | ||
| Q2 24 | $-919.2K | $-1.4M | ||
| Q1 24 | — | $-1.9M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
